KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Income from Continuing Operations: 2017-2025

Historic Income from Continuing Operations for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to $18.1 million.

  • Amneal Pharmaceuticals' Income from Continuing Operations rose 54.22% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.6 million, marking a year-over-year increase of 139.30%. This contributed to the annual value of -$73.9 million for FY2024, which is 51.55% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Income from Continuing Operations stood at $18.1 million for Q3 2025, which was down 49.08% from $35.6 million recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Income from Continuing Operations peaked at $35.6 million during Q2 2025, and registered a low of -$240.1 million during Q2 2022.
  • Moreover, its 3-year median value for Income from Continuing Operations was $16.8 million (2024), whereas its average is -$4.0 million.
  • Data for Amneal Pharmaceuticals' Income from Continuing Operations shows a peak YoY increase of 1,135.41% (in 2023) and a maximum YoY decrease of 1,495.08% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Amneal Pharmaceuticals' Income from Continuing Operations stood at -$20.4 million in 2021, then soared by 71.33% to -$5.9 million in 2022, then plummeted by 1,495.08% to -$93.4 million in 2023, then spiked by 77.75% to -$20.8 million in 2024, then spiked by 54.22% to $18.1 million in 2025.
  • Its Income from Continuing Operations stands at $18.1 million for Q3 2025, versus $35.6 million for Q2 2025 and $24.6 million for Q1 2025.